Wed.Aug 14, 2024

article thumbnail

WHO declares mpox outbreak a global health emergency

STAT

The World Health Organization on Wednesday declared the spread of mpox in multiple African countries a public health emergency of international concern, the second such declaration in the past two years called in response to transmission of the virus. The latest decision came on the recommendation of a panel of experts convened to advise WHO Director-General Tedros Adhanom Ghebreyesus on the issue.

145
145
article thumbnail

JVC-001 Vaccine Demonstrates Antibody Coverage Against Measles, Mumps, and Rubella

Pharmacy Times

The seroprotection rate of antibody titers was 100% against the 3 viruses, and geometric mean titer also increased from administration to day 43.

Vaccines 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Opinion: Better safety studies could restore America’s confidence in vaccines

STAT

In February 2021, I received my second Covid-19 shot — the newly developed vaccine that would eventually save millions of lives worldwide — with great anticipation. It proved to be a life-changing event: Two hours later as I was driving home, the shock of a sudden loud and high-pitched whistling nearly caused me to veer off the road. It was as if an audible dog whistle began blaring right next to me.

Vaccines 145
article thumbnail

Mark Cuban wants to keep shaking up healthcare. Here's Cost Plus Drug's next move

Fierce Healthcare

Entrepreneur and investor Mark Cuban wants to "f--k up" the U.S. healthcare system to make it more affordable, the billionaire told "The Daily Show" host Jon Stewart this week. | Entrepreneur and investor Mark Cuban wants to "f--k up" the U.S. healthcare system to make it more affordable, the billionaire told "The Daily Show" host Jon Stewart this week.

141
141
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Opinion: Ultra-processed foods: the tobacco of the 21st century?

STAT

At the start of the clinic where I see patients with colorectal, stomach, pancreatic, and other gastrointestinal cancers, I remarked to a colleague, “Every new patient on my schedule is under 45.” She replied, “Three of mine are … this is too many young people with cancer.” We felt as though we were in the trenches and didn’t know where the bullets were coming from.

143
143
article thumbnail

Pharmacists Can Suggest B Vitamin Intake to Treat Parkinson Disease

Pharmacy Times

Individuals with Parkinson disease reported a decrease in bacterial genes for biosynthesis of riboflavin (vitamin B2) and biotin (vitamin B7).

139
139

More Trending

article thumbnail

Elevating Stroke Care: A Pharmacy Perspective on Telestroke Services

Pharmacy Times

In recent years, telestroke services have transformed stroke care delivery, especially in rural or underserved areas.

139
139
article thumbnail

STAT+: Sudden cardiac arrest requires luck to survive. Scientists hope to turn those odds around

STAT

By definition, sudden cardiac arrest seems to come out of nowhere. The most shocking cases are when young athletes collapse on the field, but this type of calamity also strikes dedicated middle-age runners, retirees whose health problems seemed well under control, adults of all ages and class. If the person is lucky, medical help is close enough to get the heart beating again after it stops and before brain damage sets in, and the search for the hidden cause can begin.

Hospitals 142
article thumbnail

With FDA approval of Livdelzi, Gilead launches an inflammatory drug for the first time

Fierce Pharma

With an FDA appro | The FDA has approved Gilead's primary biliary cholangitis treatment Livdelzi. The drug, which was acquired in a $4.3 billion buyout of CymaBay Therapeutics six months ago, is the first inflammatory treatment launched by Gilead.

FDA 137
article thumbnail

Fair Square Medicare rolls out AI voice agents to help enroll seniors into insurance plans

Fierce Healthcare

Getting seniors enrolled into the right Medicare plan is typically an inefficient process that many older patients find confusing and frustrating, spending hours on the phone with human call center | Startup Fair Square Medicare is using advancements with generative AI to build AI-based voice agents to screen seniors for Medicare coverage and improve the customer experience.

Insurance 137
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

FDA Grants Seladelpar Accelerated Approval for Primary Biliary Cholangitis

Pharmacy Times

The decision is based on clinical findings demonstrating seladelpar’s ability to effectively regulate of alkaline phosphatase values in patients.

FDA 135
article thumbnail

Kaiser Permanente rolls out Abridge's gen AI clinical tech across 40-hospital system

Fierce Healthcare

Startup Abridge has notched it's largest partnership to date as Kaiser Permanente is making its generative AI tools for medical documentation available to more than 24,000 doctors across its system | Startup Abridge has notched it's largest partnership to date as Kaiser Permanente is making its generative AI tools for medical documentation available to more than 24,000 doctors across its system.

article thumbnail

Study Supports Bendamustine-Rituximab as Standard-of-Care in Patients With Indolent Non-Hodgkin Lymphoma

Pharmacy Times

The data builds off prior studies supporting bendamustine-rituximab as a first-line treatment for patients with non-Hodgkin lymphoma.

132
132
article thumbnail

What the data says about the telehealth market

Fierce Healthcare

In this week's episode of "Podnosis," we’re discussing the challenges and opportunities for telehealth, given some notable setbacks for the industry in recent months. | In this week's episode of "Podnosis," we’re discussing the challenges and opportunities for telehealth, given some notable setbacks for the industry in recent months.

133
133
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

J&J and Roche are the strongest companies in the biopharma industry, says S&P Global

Fierce Pharma

Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers. | Johnson & Johnson and Roche are at the top of S&P Global’s pharmaceutical industry power ratings, which assess the strength of the world’s top 17 drugmakers.

130
130
article thumbnail

Insurers push 'food is medicine' interventions but rarely weigh in on ultra-processed food

Fierce Healthcare

Cancer. Heart disease. Mental health disorders. Cognitive impairment. Stroke. Diabetes. | Evidence points to overconsumption of ultra-processed foods leading to severe health outcomes, but food is medicine interventions with insurers rarely set out to directly restrict or limit these foods from their members' diets.

Insurance 127
article thumbnail

STAT+: Gilead wins U.S. approval for drug to treat autoimmune liver disease

STAT

The Food and Drug Administration on Wednesday approved a new treatment for primary biliary cholangitis, an autoimmune liver disease mainly affecting women that causes decreased liver function, debilitating itching, and fatigue. The drug, called Livdelzi, will be sold by Gilead Sciences, following the $4.3 billion acquisition of CymaBay Therapeutics, its developer, earlier this year.

FDA 125
article thumbnail

Longevity: Anti-ageing drugs, watch out, here we come…

pharmaphorum

Recent advancements in multi-omics, artificial intelligence (AI), deep learning (DL), ageing biomarkers, precision imaging, ageing clocks, robotics, and smart technologies have empowered researchers to pinpoint common pathways amenable to drug manipulation, with encouraging data now surfacing in early human clinical trials.

116
116
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

ALS patient lived with a brain-computer interface for 7 years. Here’s what researchers learned

STAT

Brain-computer interfaces are still years, and several FDA approvals, away from being available on the market. Even though industry leaders tout their eventual use for the general public , the first users of these technologies have been and will continue to be people with disabilities.  One of the primary uses for BCIs is to provide better communication for people who have been paralyzed.

article thumbnail

Completing a successful tech transfer

pharmaphorum

CDMOs like Lannett play a critical role in tackling tech transfer challenges in the pharmaceutical industry. Learn how they navigate diverse challenges to ensure successful transfers.

115
115
article thumbnail

FDA Approves Medtronic’s Disposable CGM

Drug Topics

Medtronic also announced it has entered a global partnership with Abbott in an effort to expand CGM device options for patients living with diabetes.

FDA 112
article thumbnail

Otsuka, Click's depression DTx launches in the US

pharmaphorum

Otsuka and Click Therapeutics' first-in-class prescription digital therapeutic for depression launches in US through mobile app stores

114
114
article thumbnail

Health and Wellness Innovation Can Take Many Forms

Pharmacy Times

Roszak highlighted pharmacy data interoperability and food is medicine programs as 2 examples of innovative projects at the National Association of Chain Drug Stores.

107
107
article thumbnail

Baxter slims down again, selling kidney division to Carlyle

pharmaphorum

Baxter International has agreed to sell its kidney treatment division to private equity firm Carlyle Group in a $3.8 billion cash deal, continuing its efforts to streamline its operations and reduce debt.

111
111
article thumbnail

Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia

Fierce Pharma

Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in its competition to attract patients to their respective treatments for sickle | Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in competition to attract patients to their respective treatments for sickle cell disease.

105
105
article thumbnail

AI medtech specialist Firefly lists on Nasdaq after merger

pharmaphorum

Firefly Neuroscience lists on Nasdaq via a $45m merger with IT firm WaveDancer, as it rolls out an AI-powered platform for managing brain function.

111
111
article thumbnail

Pharma Pulse 8/14/24: Brands Love Influencers.Until Politics Get Involved, Improving Pain Self-Management Among Rural, Older Cancer Patients & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

105
105
article thumbnail

AZ gets landmark approval for Imfinzi/Lynparza combo

pharmaphorum

AstraZeneca has claimed the first regulatory approval for an immunotherapy/PARP inhibitor combination for endometrial cancer.

105
105
article thumbnail

Complying with the DSCSA

Pharmaceutical Commerce

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

FDA 105
article thumbnail

Africa on high alert as mpox cases rise quickly

pharmaphorum

The rapid spread of a new variant of mpox – previously known as monkeypox – has prompted the Africa Centers for Disease Control and Prevention (Africa CDC) to declare a public health emergency.

105
105
article thumbnail

Hidradenitis Suppurativa Treatment Shows Positive Results in Phase 3 Trial

Drug Topics

Izokibep from Affibody is a small therapeutic protein designed to inhibit IL-17A.

98
article thumbnail

China approves AstraZeneca-Daiichi Sankyo’s gastric cancer therapy

Pharmaceutical Technology

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), has received conditional approval in China for gastric cancer.

98
article thumbnail

Q&A: An Independent Pharmacist’s Hopes for PBM Reform

Drug Topics

Tom DePietro, PharmD, owner of DePietro’s Pharmacy in Dunmore, Pennsylvania, talked about current movement toward PBM reform and his hopes for the future of pharmacy.

98